Bek Muslimov is a Co-Founding Partner at Leafy Tunnel. Over the past 7 years, he’s been investing in European life sciences and technology companies. Floris Wolswijk, spoke with Bek to learn about Leafy Tunnel’s investment strategy and what brought him to invest in psychedelics.
Itay Hecht is the CEO & Co-Founder of PsyRx, an Israeli pharmaceutical producer of natural psychedelics – ibogaine and psilocybin specifically. As there will be a need for natural – but GMP grade – psychedelics, PsyRx is filling that gap.
Opioid prescriptions for pain can be a godsend. But instead of alleviating pain, opioid addiction is killing hundreds of thousands. Can psychedelics like ibogaine offer an alternative treatment option?
Now that the UK is out of Europe, could it become a hub for psychedelic research? Let’s take a look.
BrainFutures recently a report on how to make psychedelics accessible and affordable. Here are some of the insights.
Can psychedelics change your personality for the better? Let’s take a look
Can we use psychedelics to alleviate extreme suffering?
Jesse Hudson is Chief Legal Officer at Woven Science and is spearheading their El Puente initiative to give back to these communities and preserve their cultural heritage.
Peter is the CSO and co-founder of Psygen – where they make psychedelic APIs – active pharmaceutical ingredients – for research and at scale. Dive into our interview to learn about the challenges of scaling up the production of psychedelics.
The PSYCH Symposium was another great insight into how psychedelic medicine is progressing, with lots of exciting presentations & discussions.